Why Processors Decline Peptide Sellers

Most payment processors do not publish a rule against peptides. They decline and terminate peptide sellers anyway, under the broad discretion every processor agreement already gives them. That gap between what the policy says and what the reviewer does is the whole problem. A written rule is something you can read and plan around. Discretion is not, and it is why a peptide store can pass signup, process cleanly for months, and then get closed in a week.

Key takeaways

• Of eight major processors we track, only Wise names peptides as prohibited outright. Square’s published list does not mention them at all, and Square still terminates peptide sellers.
• Stripe’s nearest entry bans “incorrectly labeled research chemicals,” so the line turns on your labeling and marketing rather than on the product itself.
• Approval is not a decision about your category. It is a light screen, and the real review comes later when your volume, your pages, or your disputes bring a human to the file.
• The 2026 federal news about peptide compounding does not change any of this. It applies to pharmacies filling prescriptions, not to research-use-only ecommerce.

Do payment processors actually ban peptides?

Usually not in writing. Here is what the published policies say, taken word for word from each processor’s own page as captured in August 2026.

Processor	What the policy says about peptides	Tier
Wise	”Anabolic steroids and peptides”	Prohibited
Adyen	Names “peptides, research chemicals” inside hazardous materials, business-to-business	Restricted (B2B), prohibited (direct to consumer)
Stripe	”Incorrectly labeled research chemicals”	Prohibited
PayPal	”narcotics, steroids, certain controlled substances”	Prohibited
Square	No peptide or research-chemical category	Not listed

Only one of those is a flat ban on the word “peptide” in every context. Adyen names peptides directly and splits them, restricted for business-to-business sales and prohibited when you sell them direct to consumers. If you run an online store, the second half is the one that applies to you. Stripe’s entry is conditional, and the condition is your labeling. PayPal names steroids, which is a different class of compound, though a catalog that carries both will be read on the steroids.

Square is the one worth sitting with. Its published list says nothing about peptides or research chemicals. Square still closes peptide accounts. One merchant told us Square did exactly that in August 2026. Square said their activity met the card networks’ criteria for a terminated-merchant listing. So the absence of a rule was not the absence of risk. It just meant nothing warned them.

You can check any of these yourself in our prohibited businesses lookup, which holds the verbatim policy text for each processor.

Why the published list is not where the risk lives

Every processor agreement reserves the right to end the relationship at its own discretion. That clause, not the category list, is what closes most peptide accounts.

This matters because merchants read the list and draw the wrong conclusion. If your product is not named, it feels like you are in the clear. What you have actually found is that nobody has committed to anything. A reviewer can still look at your store, decide it does not fit the risk they want, and act on the general clause. There is no appeal to a rule that was never written.

The pattern is the same one that catches supplement brands on Stripe. Shared accounts screen lightly at signup because that is what makes instant onboarding possible. The careful look happens later, triggered by something ordinary. Your volume grows. You launch a new landing page. A month of disputes runs hot. Someone opens the file, reads the catalog for the first time, and reaches a different answer than the signup form did.

Nothing about the business got worse. The account just got read.

What actually triggers the decline

When a reviewer does open a peptide file, a short list of things decides it.

• The product line itself. Research peptides sit next to categories most risk teams already avoid. A catalog that also carries SARMs or anything sold for body composition moves you into a harder bucket.
• Human-consumption and dosing language. This is the biggest single trigger. Dosing charts, injection instructions, before-and-after photos, and results claims all read as evidence that the product is meant for people, whatever the disclaimer says.
• Health and outcome claims. Statements about healing, recovery, muscle growth, or anti-aging pull you toward the “unsafe or overclaiming” language that several policies use.
• Missing documentation. No certificates of analysis, no supplier records, and no research-use acknowledgment at checkout leaves a reviewer with nothing to weigh in your favor.
• Dispute and refund behavior. A rising chargeback rate gets the file opened in the first place. Many peptide accounts are closed during a dispute review rather than a policy review.
• The wrong merchant category code. A code that does not match what you actually sell invites a second look, and second looks rarely help.

Why “research use only” does not settle the question

Research-use-only labeling is worth having, and underwriting does look at it. It is not the shield most sellers think it is.

Under federal rules, what a product is intended for is judged by the objective picture, not by the label alone. That picture includes your advertising, your statements, and the circumstances of how you sell. A disclaimer at the bottom of a page that carries dosing instructions and testimonials does not outweigh the rest of the page. The whole offer is the evidence.

Payment reviewers apply the same logic, and they get there faster because they are not lawyers and are not trying to be. They read your site the way a customer would. If the site reads like it is selling something for people to take, the disclaimer does not change the answer.

The useful way to think about it is that research-use framing is one signal among several. We break down what research-use-only labeling actually does for a merchant account in more detail. It works when the rest of your store agrees with it. Age-gating, a research affiliation attestation at checkout, certificates of analysis, and product pages with no dosing or outcome language all point the same direction. A disclaimer sitting alone, surrounded by copy that contradicts it, points the other way.

Where the 2026 compounding news fits, and where it does not

Peptides were in the federal news twice in 2026, and neither story changes how a processor reads a research-use-only store.

The FDA keeps a list of bulk drug substances that compounding pharmacies may use under Section 503A. Nineteen peptides were moved to Category 2 in September 2023, which flags substances the agency has identified significant safety risks for. A peptide on neither Category 1 nor the approved list also cannot be legally compounded, which is the part most coverage skips. In April 2026 the FDA removed 12 peptides from Category 2 because the people who nominated them withdrew the nominations. Removal is not permission. It does not place a substance on the list or make it compoundable.

Then in July 2026 the Pharmacy Compounding Advisory Committee voted on seven peptides. It recommended adding six to the 503A list, including BPC-157, TB-500 and Semax. It voted against the seventh. The votes were narrow, and FDA staff opposed them.

Here is the part that matters for your account. That committee only advises. The FDA has not adopted the recommendation, and rulemaking after a vote like this can take more than a year. It also applies to licensed pharmacies compounding for patients with prescriptions, which is a completely different business from selling research compounds online. If you sell research-use-only peptides through a store, none of it applies to you, and citing it to a processor will not help your case.

SARMs are a harder case than peptides

If your catalog includes SARMs, expect that to drive the whole decision.

The FDA treats SARMs as unapproved new drugs. Its warning letters state plainly that labeling them as dietary supplements to work around the approval process is illegal, and enforcement has continued through 2025 and into 2026. That is a clearer federal position than the one covering most research peptides, and risk teams know it.

In practice, a mixed catalog gets underwritten on its riskiest item. If SARMs are a small part of your revenue, it is worth knowing that they may be setting the terms for everything else you sell.

What underwriting should be looking at instead

None of this means a peptide business cannot get a real merchant account. It means the decision has to be made deliberately, up front, by someone who has actually read the store.

A proper review reads the whole store at once. That means the labeling posture, the disclaimers, the age-gating, the certificates of analysis, the supplier records, and the refund and dispute profile. All of it gets settled before terms are set. The compliance questions are answered at the start, instead of surfacing as an account closure six months in.

That is the difference between an account you can build on and an account you are borrowing. Our peptide merchant accounts page covers what that review involves and what to have ready.

If you have already been declined or terminated

A decline is recoverable. A termination needs a faster answer, because the clock starts immediately. We walk through the first weeks in what happens after a peptide merchant account is terminated.

Did the processor mention the card networks’ terminated-merchant database? Start with what to do after a merchant account termination, then look at your MATCH and TMF options. A listing is not the end of card processing. It does narrow who can place you, though. The sooner it is handled, the fewer weeks you spend unable to take payments.

If you were simply declined, the useful next step is to fix what the reviewer saw before applying again. Pull the dosing language. Move the research-use acknowledgment from the footer to checkout. Get your certificates of analysis in order. Then apply somewhere that underwrites the category on purpose.